One hundred five patients were enrolled in a 12-week, randomized, prospective, double-blind, placebo-controlled trial of recombinant human gamma-interferon (rHu gamma-IFN) for the treatment of rheumatoid arthritis. Fifty-four patients received rHu gamma-IFN and 51 received placebo. Forty-two patients in each group completed the 12-week trial. Some clinical improvement occurred in both groups of patients. Although the improvement with rHu gamma-IFN was greater than that with placebo, the differences were generally not statistically significant.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/art.23361 | DOI Listing |
Publication Analysis
Top Keywords
rhu gamma-ifn
12
trial recombinant
8
treatment rheumatoid
8
rheumatoid arthritis
8
double-blind trial
4
recombinant gamma-interferon
4
gamma-interferon versus
4
versus placebo
4
placebo treatment
4
arthritis 1989
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!